Trial Profile
A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 08 Jun 2021 Results (n=57) of NCT02097238, NCT02470091 and NCT02487979 assessing efficacy patients with recurrent/refractory osteosarcoma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 03 Oct 2019 Primary endpoint (Disease Control Success) has not been met as per results published in the European Journal of Cancer.
- 03 Oct 2019 Results published in the European Journal of Cancer